Search

Now showing items 1-8 of 8

Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis

Schneider, H.; Van Rensburg, C.; Schmidt, S.; Aboo, N.; Makela, H.; Naucler, E.; Hallerback, B.; Svedberg, L-E. (2004)

Background/Aims: An intravenous formulation of esomeprazole has been developed for use in patients where oral administration is not appropriate. This study evaluated safety after 1 and 4 weeks, and efficacy after 4 weeks' ...

Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease

Van Zyl J.; Van Rensburg C.; Vieweg W.; Fischer R. (2004)

Background/Aim: Gastroesophageal reflux disease (GERD) is a prevalent disease associated with a high symptom burden and a reduced quality of life. This multicenter, randomized, double-blind study compared relief from key ...

Intrapleural streptokinase for empyema and complicated parapneumonic effusions

Diacon A.H.; Theron J.; Schuurmans M.M.; Van De Wal B.W.; Bolliger C.T. (2004)

We conducted a single-center, randomized, placebo-controlled trial to determine whether streptokinase instillations adjunctive to chest tube drainage reduce the need for surgery and improve outcome in patients with pleural ...

Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial

Tripathy, D.; Lichinitzer, M.; Lazarev, A.; MacLachlan, S. A.; Apffelstaedt, J.; Budde, M.; Bergstrom, B.; Abdi, E.; Abramson, N.; Baker, T. M.; Kirkegaard, L. W.; Schmidt, J. R.; Bell, D.; Bell, R.; Belt, R. J.; Bernstein, J. I.; Just, R. G.; Burningham, R. A.; Trafficante, B.; Caggiano, V.; Cartwright, T.; Chernozemsky, I. N.; Clingan, P.; Conkling, P.; Craig, J. B.; Grosbach, A. B.; Decker, D.; Dickman, E.; Duga, Jr. W.; Dunlap, W.; Eisenberg, P. D.; Ellerton, J.; Ettinger, M.; Ey, F.; Falkson, G.; Falkson, C.; Fink, K.; Fleagle, J.; Forlenza, T.; Gorbunova, V. A.; Gross, G. E.; Grotes, T.; Grygiel, J.; Gudgeon, A.; Werner, I. D.; Hacking, D.; Harrer, G. W.; Harvey, V.; Hirsch, R.; Koletsky, A.; Jordaan, J. P.; Cash, D. K.; Khasanov, R. Sh.; LaFata, J. A.; Lafollette, S.; Koshla, P.; Landers, G.; Lebos, H. C.; Wade, J. L.; Lowenthal, T.; Lyons, R.; McLachlan, S. A.; Murray, R.; Perez, D.; Phadke, K.; Rapoport, B.; Rausch, P. G.; Robinson, B.; Sarna, G.; Saven, A.; Schwartz, M.; Semiglazov, V. F.; Stewart, J.; Sunderland, K.; Thomas, L.; Vogel, C. L.; Martinez Rio, M.; Vorobiof, D. A.; Wilks, S.; Woolley, P. (2004)

Background: We report the first results of a randomized trial assessing a new oral aminobisphosphonate, ibandronate, in patients with bone metastases from breast cancer. Patients and methods: Patients (n = 435) received ...

Comparison of a new desktop spirometer (Spirospec) with a laboratory spirometer in a respiratory out-patient clinic

Swart F.; Schuurmans M.M.; Heydenreich J.C.; Pieper C.H.; Bolliger C.T. (2004)

BACKGROUND: The performance of spirometers is often evaluated under ideal conditions with computergenerated waveforms or in vivo testing with healthy subjects. Real-life conditions are less ideal because of comorbidities, ...

A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia

Emsley R.; Turner H.J.; Schronen J.; Botha K.; Smit R.; Oosthuizen P.P. (2004)

Background: While the atypical antipsychotics should ultimately reduce the prevalence of tardive dyskinesia, it is likely to remain a significant clinical problem for a long time to come. No strategy has clearly emerged ...

Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder

Seedat S.; Stein M.B. (2004)

Background: Generalized social anxiety disorder (GSAD) is a pervasive form of social anxiety that affects approximately 5% of persons in the community. Among evidence-based pharmacologic treatments for the disorder, selective ...

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trialRecombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

Opal, S.; Laterre, P-F.; Abraham, E.; Francois, B.; Wittebole, X.; Lowry, S.; Dhainaut, J-F.; Warren, B.; Dugernier, T.; Lopez, A.; Sanchez, M.; Demeyer, I.; Jauregui, L.; Lorente, J. A.; McGee, W.; Reinhart, K.; Kljucar, S.; Souza, S.; Pribble, J.; Opal, S.; Laterre, P-F.; Abraham, E.; Francois, B.; Wittebole, X.; Lowry, S.; Dhainaut, J-F.; Warren, B.; Dugernier, T.; Lopez, A.; Sanchez, M.; Demeyer, I.; Jauregui, L.; Lorente, J. A.; McGee, W.; Reinhart, K.; Kljucar, S.; Souza, S.; Pribble, J. (2004)

Objective: Platelet-activating factor (PAF) and structurally-related oxidized phospholipids are proinflammatory mediators in systemic inflammatory states such as severe sepsis. The enzyme platelet-activating factor ...